AbbVie Company Profile (NYSE:ABBV)

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:ABBV
  • CUSIP: 00287Y10
  • Web: www.abbvie.com
Capitalization:
  • Market Cap: $144.53659 billion
  • Outstanding Shares: 1,594,094,000
Average Prices:
  • 50 Day Moving Avg: $85.49
  • 200 Day Moving Avg: $72.96
  • 52 Week Range: $55.06 - $92.61
P/E:
  • Trailing P/E Ratio: 17.31
  • Foreward P/E Ratio: 13.77
  • P/E Growth: 1.16
Sales & Book Value:
  • Annual Revenue: $26.71 billion
  • Price / Sales: 5.43
  • Book Value: $3.77 per share
  • Price / Book: 24.15
Dividend:
  • Annual Dividend: $2.56
  • Dividend Yield: 2.8%
Profitability:
  • EBITDA: $11.57 billion
  • Net Margins: 24.77%
  • Return on Equity: 150.27%
  • Return on Assets: 12.52%
Debt:
  • Debt-to-Equity Ratio: 5.63%
  • Current Ratio: 1.38%
  • Quick Ratio: 1.25%
Misc:
  • Average Volume: 6.28 million shs.
  • Beta: 1.51
  • Short Ratio: 5.37
 

Frequently Asked Questions for AbbVie (NYSE:ABBV)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Friday, September 8th. Shareholders of record on Friday, October 13th will be given a dividend of $0.64 per share on Wednesday, November 15th. This represents a $2.56 annualized dividend and a yield of 2.81%. The ex-dividend date of this dividend is Thursday, October 12th. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its Board of Directors has approved a stock repurchase plan on Sunday, April 9th 2017, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 5% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board believes its stock is undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings results on Friday, July, 28th. The company reported $1.42 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.40 by $0.02. The company earned $6.94 billion during the quarter, compared to analysts' expectations of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The company's revenue for the quarter was up 7.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.26 earnings per share. View AbbVie's Earnings History.

When will AbbVie make its next earnings announcement?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY17 earnings guidance on Friday, July, 28th. The company provided earnings per share (EPS) guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.53.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?

16 brokerages have issued 12 month price objectives for AbbVie's shares. Their forecasts range from $60.00 to $115.00. On average, they anticipate AbbVie's stock price to reach $93.33 in the next year. View Analyst Ratings for AbbVie.

What are analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

  • 1. UBS AG analysts commented, "For other pipeline products, we already included appropriate risk-adj estimates and in some cases significant risk adj sales (Rova-T)," (9/25/2017)
  • 2. According to Zacks Investment Research, "AbbVie’s key drug Humira is performing well and should continue to be driven by growing awareness, favorable clinical data, new indications and expansion into new markets. Moreover, Imbruvica has multi-billion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Investor focus will be on the stock with several late-stage data-readouts are expected in 2017. AbbVie’s shares outperformed the large-cap pharma industry so far this year. However, Viekira faces intense pricing and competitive pressure in the HCV market. Though Humira is doing well, the company is concerned about the product’s long-term prospects owing to the potential biosimilar competition. Estimates remained stable ahead of the company’s Q2 earnings release. AbbVie has had a mixed record of earnings surprises in the recent quarters. " (7/13/2017)
  • 3. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:

  • Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
  • William J. Chase, Executive Vice President, Chief Financial Officer
  • Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
  • Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
  • Carlos Alban, Executive Vice President - Commercial Operations
  • Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
  • Timothy J. Richmond, Senior Vice President - Human Resources
  • Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
  • Robert A. Michael, Vice President, Controller
  • Robert J. Alpern M.D., Independent Director

Who owns AbbVie stock?

AbbVie's stock is owned by a number of of institutional and retail investors. Top institutional investors include Park National Corp OH (0.02%), Tandem Investment Advisors Inc. (0.01%), Osborn Williams & Donohoe LLC (0.01%), Neville Rodie & Shaw Inc. (0.01%), Fulton Bank N.A. (0.00%) and Bridges Investment Management Inc. (0.00%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including Bridges Investment Counsel Inc., Private Asset Management Inc., Fulton Bank N.A., Osborn Williams & Donohoe LLC, Neville Rodie & Shaw Inc., Park National Corp OH, Bridges Investment Management Inc. and Tandem Investment Advisors Inc.. Company insiders that have sold AbbVie stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was purchased by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp, Eqis Capital Management Inc. and Amarillo National Bank. View Insider Buying and Selling for AbbVie.

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of AbbVie stock can currently be purchased for approximately $91.04.


MarketBeat Community Rating for AbbVie (NYSE ABBV)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  605 (Vote Outperform)
Underperform Votes:  349 (Vote Underperform)
Total Votes:  954
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AbbVie (NYSE:ABBV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $93.33 (2.52% upside)
Consensus Price Target History for AbbVie (NYSE:ABBV)
Price Target History for AbbVie (NYSE:ABBV)
Analysts' Ratings History for AbbVie (NYSE:ABBV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Jefferies Group LLCBoost Price TargetBuy$107.00 -> $115.00N/AView Rating Details
10/13/2017Barclays PLCBoost Price TargetEqual Weight$90.00N/AView Rating Details
10/11/2017Cowen and CompanyUpgradeMarket Perform -> Outperform$91.17 -> $105.00N/AView Rating Details
10/2/2017Leerink SwannUpgradeMarket Perform -> Outperform$89.00 -> $106.00MediumView Rating Details
10/1/2017Credit Suisse GroupReiterated RatingNeutral$74.00 -> $94.00MediumView Rating Details
9/30/2017Evercore ISIReiterated RatingOutperform$95.00 -> $100.00MediumView Rating Details
9/28/2017BMO Capital MarketsReiterated RatingHold$66.00LowView Rating Details
9/29/2017ArgusBoost Price TargetBuy$90.00 -> $110.00LowView Rating Details
9/29/2017Morgan StanleyBoost Price TargetEqual Weight$70.00 -> $95.00LowView Rating Details
9/28/2017Deutsche Bank AGBoost Price TargetHold$88.00LowView Rating Details
9/15/2017Piper Jaffray CompaniesReiterated RatingBuy$100.00HighView Rating Details
9/13/2017SunTrust Banks, Inc.Reiterated RatingBuy$95.00LowView Rating Details
9/8/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$85.00 -> $100.00LowView Rating Details
6/22/2017Societe GeneraleUpgradeHold -> BuyLowView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016Citigroup Inc.DowngradeBuy -> Neutral$60.00N/AView Rating Details
9/8/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$75.00 -> $73.00N/AView Rating Details
9/1/2016Raymond James Financial, Inc.Initiated CoverageOutperform$82.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$59.00N/AView Rating Details
(Data available from 10/17/2015 forward)

Earnings

Earnings History for AbbVie (NYSE:ABBV)
Earnings by Quarter for AbbVie (NYSE:ABBV)
Earnings History by Quarter for AbbVie (NYSE ABBV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2017$1.38N/AView Earnings Details
7/28/2017Q2 2017$1.40$1.42$6.93 billion$6.94 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.26$1.28$6.49 billion$6.54 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AbbVie (NYSE:ABBV)
Current Year EPS Consensus Estimate: $5.53 EPS
Next Year EPS Consensus Estimate: $6.61 EPS

Dividends

Current Dividend Information for AbbVie (NYSE:ABBV)
Next Dividend:11/15/2017
Annual Dividend:$2.56
Dividend Yield:2.81%
Dividend Growth:12.50% (3 Year Average)
Payout Ratio:62.90% (Trailing 12 Months of Earnings)
46.29% (Based on This Year's Estimates)
38.73% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

Dividend History by Quarter for AbbVie (NYSE ABBV)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/8/2017Quarterly$0.642.94%10/12/201710/13/201711/15/2017
6/23/2017quarterly$0.643.52%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.644.14%4/11/20174/13/20175/15/2017
10/28/2016quarterly$0.644.44%1/11/20171/13/20172/15/2017
9/12/2016quarterly$0.573.56%10/12/201610/14/201611/15/2016
6/17/2016quarterly$0.573.8%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.574.2%4/13/20164/15/20165/16/2016
11/2/2015quarterly$0.573.6%1/13/20161/15/20162/16/2016
9/14/2015quarterly$0.513.46%10/13/201510/15/201511/14/2015
6/19/2015quarterly$0.512.94%7/13/20157/15/20158/14/2015
2/20/2015quarterly$0.513.33%4/13/20154/15/20155/15/2015
10/20/2014quarterly$0.493.48%1/13/20151/15/20152/13/2015
9/19/2014quarterly$0.422.86%10/10/201410/15/201411/17/2014
6/19/2014quarterly$0.423.15%7/11/20147/15/20148/15/2014
2/20/2014quarterly$0.423.29%4/11/20144/15/20145/15/2014
12/12/2013quarterly$0.403.06%1/13/20141/15/20142/14/2014
9/19/2013quarterly$0.403.34%10/10/201310/15/201311/15/2013
6/20/2013quarterly$0.403.75%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.404.19%4/11/20134/15/20135/15/2013
1/7/2013special$0.401/11/20131/15/20132/15/2013
1/4/2013quarterly$0.401/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AbbVie (NYSE:ABBV)
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 68.25%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2017Robert A MichaelVPSell6,699$88.00$589,512.00View SEC Filing  
9/11/2017Azita Saleki-GerhardtSVPSell8,300$85.02$705,666.00View SEC Filing  
8/7/2017Richard A GonzalezChairmanSell193,131$71.00$13,712,301.00View SEC Filing  
8/4/2017Richard A GonzalezChairmanSell87,899$71.02$6,242,586.98View SEC Filing  
8/3/2017Richard A GonzalezCEOSell65,861$71.00$4,676,131.00View SEC Filing  
7/31/2017Edward J RappDirectorBuy4,000$70.45$281,800.00View SEC Filing  
7/31/2017Henry O GosebruchInsiderSell18,000$70.09$1,261,620.00View SEC Filing  
6/14/2017Carlos AlbanEVPSell45,800$70.00$3,206,000.00View SEC Filing  
6/14/2017Laura J SchumacherInsiderSell79,800$70.00$5,586,000.00View SEC Filing  
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.28View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.79View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.00View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.16View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.30View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.75View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.32View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.70View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.41View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AbbVie (NYSE:ABBV)
Latest Headlines for AbbVie (NYSE:ABBV)
Source:
DateHeadline
americanbankingnews.com logo Analysts Anticipate AbbVie Inc. (ABBV) Will Post Earnings of $1.38 Per Share
www.americanbankingnews.com - October 17 at 6:28 AM
investorplace.com logoAbbVie (ABBV) a Buy on Healthy Earnings Momentum
investorplace.com - October 16 at 1:22 PM
americanbankingnews.com logoAbbVie Inc. (ABBV) Rating Increased to Outperform at Cowen and Company
www.americanbankingnews.com - October 16 at 12:50 AM
fool.com logoBetter Buy: AbbVie Inc. vs. Merck -- The Motley Fool - Motley Fool
www.fool.com - October 15 at 1:22 AM
finance.yahoo.com logoBetter Buy: AbbVie Inc. vs. Merck
finance.yahoo.com - October 14 at 8:19 PM
americanbankingnews.com logoAbbVie Inc. (ABBV) Receives "Neutral" Rating from UBS AG
www.americanbankingnews.com - October 13 at 10:44 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in AbbVie (ABBV) Stock?
finance.yahoo.com - October 13 at 8:23 PM
finance.yahoo.com logoNew Law May Pressure Drug Prices
finance.yahoo.com - October 13 at 8:23 PM
finance.yahoo.com logoWhy 2017 Could Be This Stock's Best Year Yet
finance.yahoo.com - October 13 at 8:23 PM
americanbankingnews.com logoAbbVie Inc. (ABBV) PT Raised to $90.00 at Barclays PLC
www.americanbankingnews.com - October 13 at 7:34 PM
finance.yahoo.com logoFundamental Equity Analysis – Consolidated Research on Johnson & Johnson, Home Depot, Adobe, Disney, AbbVie, and eBay – Developing Opportunities, Future Expectations, and Projections
finance.yahoo.com - October 13 at 3:18 PM
finance.yahoo.com logoCancer Space Update: Lung & Breast Cancer Studies in Focus
finance.yahoo.com - October 13 at 3:18 PM
finance.yahoo.com logo4 things that might surprise investors this earnings season
finance.yahoo.com - October 13 at 3:18 PM
reuters.com logoAbbVie, Abbott duck Depakote off-label marketing case on appeal - Reuters
www.reuters.com - October 12 at 8:21 PM
nasdaq.com logoIs the Options Market Predicting a Spike in AbbVie (ABBV) Stock? - Nasdaq
www.nasdaq.com - October 12 at 3:18 PM
nasdaq.com logoAbbVie Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - October 12 at 3:18 PM
finance.yahoo.com logoTop 5 Biotech Stocks for 2017
finance.yahoo.com - October 12 at 3:18 PM
finance.yahoo.com logoAbbVie: You're Upgrading It…Now?
finance.yahoo.com - October 11 at 8:29 PM
finance.yahoo.com logoIs AbbVie the Best Dividend Stock in Healthcare?
finance.yahoo.com - October 11 at 8:29 PM
finance.yahoo.com logoHow Safe Is AbbVie's Dividend?
finance.yahoo.com - October 11 at 8:29 PM
fool.com logoHow Safe Is AbbVie's Dividend?
www.fool.com - October 11 at 7:40 PM
seekingalpha.com logoHurricane-related damage could cause shortages of 40 drugs - FDA - Seeking Alpha
seekingalpha.com - October 11 at 3:27 PM
nasdaq.com logoAbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for October 12, 2017 - Nasdaq
www.nasdaq.com - October 11 at 3:26 PM
reuters.com logoBRIEF-AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology
www.reuters.com - October 10 at 8:19 PM
finance.yahoo.com logo3 Healthcare Dividend Stocks Ideal for Retirees
finance.yahoo.com - October 10 at 8:19 PM
finance.yahoo.com logoAbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology
finance.yahoo.com - October 10 at 8:19 PM
investorplace.com logoHold Recommendation for AbbVie (ABBV) Stock Kept - Investorplace.com
investorplace.com - October 10 at 3:19 PM
seekingalpha.com logoCalifornia enacts law aimed at corralling high drug prices - Seeking Alpha
seekingalpha.com - October 10 at 3:19 PM
nasdaq.com logoEx-Dividend Reminder: Foot Locker, Patterson Companies and AbbVie - Nasdaq
www.nasdaq.com - October 10 at 3:19 PM
americanbankingnews.com logoAbbVie (ABBV) and Its Competitors Head to Head Comparison
www.americanbankingnews.com - October 9 at 6:28 PM
finance.yahoo.com logoAbbVie to Host Third-Quarter 2017 Earnings Conference Call
finance.yahoo.com - October 9 at 3:29 PM
investorplace.com logoHold Recommendation for AbbVie (ABBV) Stock Kept
investorplace.com - October 9 at 11:37 AM
fool.com logoAbbVie's Fast Becoming a Top Stock to Buy Now - Motley Fool
www.fool.com - October 8 at 3:15 PM
finance.yahoo.com logoAbbVie's Fast Becoming a Top Stock to Buy Now
finance.yahoo.com - October 8 at 3:15 PM
finance.yahoo.com logo3 Best Healthcare Dividend Aristocrat Stocks You Can Buy Right Now
finance.yahoo.com - October 8 at 3:15 PM
americanbankingnews.com logoContrasting AbbVie (ABBV) & Its Rivals
www.americanbankingnews.com - October 7 at 6:28 PM
americanbankingnews.com logoAbbVie Inc. (ABBV) Declares $0.64 Quarterly Dividend
www.americanbankingnews.com - October 7 at 10:50 AM
bizjournals.com logoSeeger Weiss LLP Reports: Jury Awards over $140 Million in Compensatory and Punitive Damages to Man Injured by AbbVie Drug AndroGel
www.bizjournals.com - October 6 at 8:44 PM
reuters.com logoAbbVie hit with $140 mln verdict in AndroGel trial -lawyer - Reuters
www.reuters.com - October 6 at 3:42 PM
reuters.com logoSecond US jury finds AbbVie misrepresented risks of AndroGel - Reuters
www.reuters.com - October 6 at 3:42 PM
seekingalpha.com logoBest Healthcare Stocks: AbbVie - Seeking Alpha
seekingalpha.com - October 6 at 3:42 PM
finance.yahoo.com logoGilead Sciences & AbbVie: Mother Always Told Me to Share
finance.yahoo.com - October 6 at 3:42 PM
fool.com logoEverything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?
www.fool.com - October 6 at 7:43 AM
nasdaq.com logoAbbVie hit with $140 mln verdict in AndroGel trial
www.nasdaq.com - October 5 at 8:09 PM
finance.yahoo.com logoAbbVie hit with $140 mln verdict in AndroGel trial -lawyer
finance.yahoo.com - October 5 at 8:09 PM
seekingalpha.com logoAbbVie suffers second trial loss over testosterone drug risk
seekingalpha.com - October 5 at 7:19 PM
americanbankingnews.com logoHead-To-Head Comparison: AbbVie (ABBV) vs. Its Competitors
www.americanbankingnews.com - October 5 at 2:28 PM
nasdaq.com logoAbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why
www.nasdaq.com - October 5 at 12:39 PM
finance.yahoo.com logoAbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why
finance.yahoo.com - October 5 at 12:39 PM
americanbankingnews.com logoInvestors Purchase High Volume of AbbVie Put Options (ABBV)
www.americanbankingnews.com - October 5 at 3:14 AM

Social

Chart

AbbVie (ABBV) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.